Can Anastrozole Cause Weight Gain?

Clinical trial evidence consistently shows that anastrozole does not cause more weight gain than a placebo. In the large IBIS-II prevention trial, women on anastrozole gained an average of about 0.8 kg over 12 months compared with 0.5 kg in the placebo group, a difference that was not statistically significant. Yet many people taking anastrozole feel certain the drug has changed their body, and they are not entirely wrong. The story is more nuanced than the scale alone suggests, and it involves shifts in body composition, changes in physical activity driven by side effects, and the broader metabolic backdrop of the postmenopausal years.

What the Largest Trials Found

The best evidence on this question comes from two major trials. The IBIS-II trial compared anastrozole against a placebo in postmenopausal women at high risk of breast cancer. After a year, both groups gained a small amount of weight, and the difference between them was trivial. The ATAC trial, which treated women who already had early-stage breast cancer, compared anastrozole against tamoxifen. Again, weight gain after 12 months was nearly identical in both groups, with the anastrozole arm averaging about 1.4 kg and the tamoxifen arm about 1.5 kg.¹

These are not small or poorly designed studies. The ATAC trial enrolled over 9,000 women and followed them for years. The IBIS-II trial was placebo-controlled, which is the gold standard for isolating a drug’s true effect from whatever would have happened anyway. Both point in the same direction: anastrozole itself does not appear to push the number on the scale any higher than aging, menopause, and a cancer diagnosis already do on their own.

The Body Composition Story Is More Complicated

A stable weight does not mean nothing is happening underneath. A closer analysis of the IBIS-II data using body-composition measurements found that women on anastrozole had, on average, about 0.1 kg more body fat and about 0.3 kg less fat-free mass than those on placebo at the 9-to-18-month mark. Neither difference reached statistical significance, and the researchers concluded that any shift was likely less than a kilogram and therefore unlikely to be clinically meaningful.²

Other research paints a slightly different picture when you look at women further into treatment. A study of early breast cancer patients who completed a full course of aromatase inhibitor therapy found that fat mass rose by about 8 to 10 percent while lean mass dropped by roughly 3 percent over the treatment period.³ A separate study comparing postmenopausal breast cancer patients on aromatase inhibitors with matched healthy controls found that patients had lower lean mass across almost all body compartments, along with higher peripheral body fat percentage, even though total fat mass and trunk fat were similar.⁴

This is the pattern that frustrates so many patients: the scale might not budge much, but clothes fit differently, muscle tone decreases, and the body feels softer. That experience is real. It reflects a shift from lean tissue toward fat tissue, which can happen without any dramatic change in total body weight.

Why So Many People Blame the Drug

If anastrozole itself barely moves the needle, why do so many patients report gaining weight after starting it? Several factors overlap in a way that makes the drug a convenient scapegoat.

First, anastrozole is typically prescribed to postmenopausal women, a population already prone to gradual weight gain and shifts in fat distribution due to falling estrogen levels. The natural trajectory for many women in their fifties and sixties includes some creep upward on the scale each year. Starting a new medication right around the time that trajectory is steepest makes it easy to attribute the change to the pill.

Second, anastrozole commonly causes joint pain and stiffness. For some women, these musculoskeletal symptoms are severe enough to reduce physical activity. Less movement means fewer calories burned and, over time, weight gain. The drug is not directly making the body store more fat; it is indirectly making it harder to stay active.

Third, a breast cancer diagnosis itself brings disruptions: surgery, possible chemotherapy or radiation beforehand, emotional stress, changes in appetite, and sometimes corticosteroid use during treatment. A study of 309 women on adjuvant endocrine therapy found that by five years, roughly two-thirds of premenopausal participants and over 40 percent of postmenopausal participants had experienced clinically meaningful weight gain. Among premenopausal women, factors associated with that gain included pain interference and receipt of an aromatase inhibitor, but also mastectomy and race, suggesting the weight gain is driven by a web of interacting factors rather than any one drug.⁵

Does Anastrozole Affect Metabolism?

Anastrozole works by blocking the aromatase enzyme, which converts androgens into estrogen. Because estrogen plays a role in how the body handles insulin and distributes fat, suppressing it raises a reasonable question about metabolic health. The answer is mixed.

A crossover study in healthy young men found that anastrozole modestly reduced insulin sensitivity at lower insulin doses, and also lowered total cholesterol slightly compared with placebo. However, it did not change weight, body mass index, or percentage of body fat.⁶ That reduced insulin sensitivity is worth noting because over years it could theoretically nudge the body toward storing more fat, but in the trials we have, that theoretical risk has not translated into measurable weight gain.

The study in postmenopausal breast cancer patients mentioned earlier did find higher insulin resistance in women on aromatase inhibitors compared with healthy controls.⁴ Whether that is driven primarily by the drug, by the cancer diagnosis, by reduced physical activity, or by a combination remains unclear. The research suggests anastrozole nudges metabolism in an unfavorable direction without, on its own, causing dramatic changes in body weight.

What About Men Taking Anastrozole?

Anastrozole is sometimes prescribed off-label to men, often to raise testosterone-to-estrogen ratios in the context of low testosterone or in transgender men. The data in male populations aligns with what we see in women: the drug does not seem to cause weight gain.

In the crossover study of healthy men described above, no significant differences in weight, body mass index, or body fat percentage were seen between the anastrozole and placebo phases.⁷ A trial in hypogonadal older men given anastrozole or placebo also reported no change in body composition or strength.⁸ An earlier study of estrogen suppression in men found no significant changes in fat mass, fat-free mass, or body mass index.⁹

An interesting piece of evidence comes from a study of transgender men. Those treated with testosterone plus anastrozole showed no change in liver fat or visceral fat volume over 12 weeks. In contrast, trans men on testosterone alone (without anastrozole) saw liver fat increase and visceral fat rise by about a third over a longer follow-up. The researchers were studying the role of estrogen conversion in fat metabolism, and the results suggest that blocking aromatase in this context may actually prevent some fat accumulation, though the study was small and the follow-up periods differed between groups.¹⁰

Does Your Weight Affect How Well Anastrozole Works?

This is a question many patients never think to ask, but it matters. There is accumulating evidence that body weight can influence how effectively anastrozole suppresses estrogen and prevents cancer recurrence.

An analysis from the ATAC trial found that the benefit of anastrozole over tamoxifen was greater in thinner women. The researchers suggested that higher doses or more potent aromatase inhibitors might be needed for overweight women, though they cautioned the finding needed independent confirmation.¹¹ A more striking result came from the ABCSG-6a trial, which looked at extended adjuvant anastrozole. Normal-weight patients who received three additional years of anastrozole roughly halved their risk of recurrence and death. Overweight and obese patients, by contrast, derived no measurable benefit from the extra treatment.¹²

The likely explanation is that fat tissue itself produces estrogen through its own aromatase activity. The more fat tissue you carry, the more estrogen your body generates, and the harder it is for a standard dose of anastrozole to fully suppress that production. This does not mean anastrozole is useless for overweight patients, but it does mean that managing weight could have a direct bearing on how well the treatment works.

Why Weight Gain During Treatment Still Matters

Even if anastrozole is not the direct cause, weight gain during breast cancer treatment is not just a cosmetic concern. A systematic review and meta-analysis found that central adiposity was associated with higher all-cause mortality in breast cancer patients, and that large weight gains were linked to worse outcomes including higher breast cancer-specific mortality and recurrence risk.¹³ Not all studies agree on the recurrence question: one long-term study of breast cancer survivors found that the recurrence risk was not significantly different between those who gained weight and those who did not.¹⁴ The overall signal, though, is that keeping weight stable during and after treatment is a reasonable goal for both general health and cancer-related outcomes.

What Actually Helps

Because the body composition changes during aromatase inhibitor therapy involve losing lean mass and gaining fat, exercise is the single most evidence-backed intervention. A 12-month trial specifically studied breast cancer survivors on aromatase inhibitors and found that a combined resistance and aerobic exercise program led to meaningful improvements: the exercise group gained lean body mass while the usual-care group lost it, body fat percentage dropped in the exercise group while it rose in the usual-care group, and body mass index fell in exercisers while it crept up in non-exercisers.¹⁵

Resistance training deserves particular emphasis. The lean-mass loss associated with aromatase inhibitors and with aging in general is best counteracted by loading muscles, not just by walking or cycling. The trial above included both resistance and aerobic components, and the lean-mass gains are a hallmark of resistance work.

Diet matters too, though the evidence suggests it is harder to achieve lasting results with dietary changes alone. Clinical guidelines recommend a nutritional assessment close to diagnosis, and experts stress that diet quality and weight management should be integrated into standard cancer care rather than treated as an afterthought.¹⁶ That said, building in structured exercise alongside dietary attention is more effective than focusing on food alone.

Individual Variation and Pharmacogenomics

Not everyone metabolizes anastrozole the same way. The drug is processed through liver enzymes and acts on the aromatase enzyme itself, and genetic differences in the genes encoding these proteins can produce meaningful variation in how much estrogen is actually suppressed, how much drug circulates in the bloodstream, and what side effects occur. Some studies have linked genetic variants in the CYP19A1 and ESR1 genes to differences in drug-related side effects, though researchers caution that these findings still need more validation before they can guide clinical decisions.¹⁷ Variants in CYP3A and UGT1A, which help break down anastrozole, also contribute to variability in how the drug behaves from person to person.¹⁸

What this means in practice is that two patients on the same dose of anastrozole may experience very different levels of estrogen suppression and very different side-effect profiles. If one patient gains weight and another does not, genetics could be part of the explanation, though the research has not yet advanced to the point where a genetic test can predict who will gain weight on the drug. For now, the take-home point is that your individual experience may not match the averages from large trials, and that does not mean the trials are wrong or that your experience is imaginary. Both can be true at once.

Premenopausal Versus Postmenopausal Patients

Aromatase inhibitors are increasingly used in premenopausal women with breast cancer, typically alongside ovarian suppression therapy. The weight trajectory in this group looks notably different. In the study of 309 women on adjuvant endocrine therapy, premenopausal participants had a five-year cumulative incidence of clinically meaningful weight gain of about 67 percent, compared with about 43 percent in postmenopausal women.⁵ Premenopausal women are undergoing a more abrupt hormonal shift, essentially being pushed into a medically induced menopause, which likely amplifies the metabolic disruption compared with women who were already postmenopausal when they started treatment.

If you are premenopausal and starting anastrozole with ovarian suppression, the weight gain risk is real and higher than what the classic postmenopausal trial data would suggest. Proactive attention to exercise and nutrition from the start of treatment, rather than after changes have already occurred, is the most practical approach based on current evidence.

1
PubMed. Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer
2
PubMed Central. Body composition changes during breast cancer preventive treatment with anastrozole: Findings from the IBIS-II trial
3
PubMed Central. Body composition in early breast cancer patients treated with adjuvant aromatase inhibitors: Does dietary counseling matter?
4
The Journal of Clinical Endocrinology & Metabolism. Higher Insulin Resistance and Adiposity in Postmenopausal Women With Breast Cancer Treated With Aromatase Inhibitors
5
Springer. Factors associated with weight gain in pre- and post-menopausal women receiving adjuvant endocrine therapy for breast cancer
6
PubMed Central. Aromatase Inhibition Reduces Insulin Sensitivity in Healthy Men
7
The Journal of Clinical Endocrinology & Metabolism. Aromatase Inhibition Reduces Insulin Sensitivity in Healthy Men
8
PubMed. Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial
9
The Journal of Clinical Endocrinology & Metabolism. Estrogen Suppression in Males: Metabolic Effects
10
The Journal of Clinical Endocrinology & Metabolism. Sex Steroids Regulate Liver Fat Content and Body Fat Distribution in Both Men and Women: A Study in Transgender Persons
11
PubMed. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial
12
British Journal of Cancer. The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer
13
PubMed Central. Associations of adiposity and weight change with recurrence and survival in breast cancer patients: a systematic review and meta-analysis
14
PubMed Central. Determinants of Weight Gain During Adjuvant Endocrine Therapy and Association of Such Weight Gain With Recurrence in Long-term Breast Cancer Survivors
15
PubMed Central. The effect of exercise on body composition and bone mineral density in breast cancer survivors taking aromatase inhibitors
16
PubMed Central. Obese Breast Cancer Patients and Survivors: Management Considerations
17
PubMed. Personalizing aromatase inhibitor therapy in patients with breast cancer
18
Pharmacogenetics and Genomics. The influence of genetic polymorphisms on the efficacy and side effects of anastrozole in postmenopausal breast cancer patients